US Stock Movement | Hutchmed (HCM.US) rises over 3%, submits NDA to FDA for collaborative therapy of Savolitinib and Osimertinib

According to Golden Ten Data APP, on Wednesday, HUTCHMED (HCM.US) rose more than 3%, closing at $14.59. In terms of news, on September 29, HUTCHMED announced that AstraZeneca had submitted a new drug application to the US FDA for the combination therapy of Orpathys and Tagrisso. This therapy is intended for the treatment of patients with locally advanced or metastatic non-small cell lung cancer who have MET overexpression or amplification and experienced disease progression during or after EGFR TKI therapy. The global phase III SAFFRON study showed that this combination therapy demonstrated improvements in both progression-free survival and overall survival.